Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
European Consortium for Stem Cell Therapy for Neurodegenerative Diseases (NEUROSTEMCELL)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Italy,Sweden,Germany,Sweden,United Kingdom,France,United Kingdom,United Kingdom,Denmark,United States
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-12-01
End date: 2013-05-31
Duration (months): 54.0
Total project cost (EUR): 15842632.0
EU funding (EUR): 11900000.0
Participants: 13
Project status: CLOSED

The NEuroStemCell consortium will foster collaboration between leading European experimental and clinical researchers in order to maximise the prospects for successful clinical trials of stem cell therapy for Parkinson&apos;s (PD) and Huntington&apos;s (HD) Disease. The activities will be driven by a Clinical WorkPackage (WP), which will set the requirements, and monitor and guide advances in development of the most promising cells. The goal is to compare different stem cell sources with respect to their capcity to generate mesencephalic Dopaminergic and striatal GABAergic neurons suitable for neuronal cell replacement. The major sources will be neuralised Embryonic Stem (ES) cells, adherent Neural Stem (NS) cell lines and short term expanded Ventral Midbrain neural stem cells/progenitors grown as Neurospheres (VMN). Two exploratory WPs will use extrinsic cues to specify neuronal differentiation and compare rigorously the different human stem cell lines and their progeny in giving rise to authentic neurons. WP3 will integrate long-term assessements of functional (motor and cognitive) recovery in appropriate animal models of PD and HD, and WP4 will exploit non-invasive in vivo imaging to evaluate the survival, composition, integration and functional impact of the donor cells in host brain. These two WPs will also provide the elements necessary to standardise the extent of recovery as a function of cell replacement and integration. In WP5, three SMEs will generate the technologies for manufacturing and scale-up of safe, fully traceable, efficacious and banked stocks of cells ready for clinical use. Regulatory and ethical requirements will be considered in the Clinical WP which also incorporates training. Building on the successful experience of the FPVI EuroStemCell project, NEuroStemCell will provide a focal point for European researchers engaged in the translational aspects of stem cell-based strategies to develop cures for PD and HD

Keywords: cell therapy,stem cell lines,parkinson,huntington,cell banks
Use of innovative strategies for beta-cell imaging in diabetes mellitus (BETAIMAGE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Switzerland,Germany,Belgium,Finland,Germany,Germany
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-10-01
End date: 2013-03-31
Duration (months): 54.0
Total project cost (EUR): 7086487.59
EU funding (EUR): 5447136.0
Participants: 10
Project status: CLOSED

The development of sensitive, non-invasive methods for the characterisation and quantification of beta-cell mass would greatly enhance our means for gaining understanding of the pathophysiology of diabetes and allow the development of novel therapies to prevent, halt and reverse the disease. The aim of this project is to develop and apply innovative approaches for beta-cell imaging, the emphasis being on beta-cell mass regulation (loss and neogenesis) with the perspective of entering initial clinical trials. For this purpose, our approach is to: (1) Focus on imaging technologies offering the potential to enter clinical trials during the runtime of the project. Since beta cells contribute only marginally (1-2%) to the total mass of the pancreas, a highly sensitive method for clinical imaging is required. BETA IMAGE will focus on positron emission tomography (PET) relying on chemical resolution, i.e. the specificity of a radiolabelled tracer molecule. The lead compound will be radiolabelled Exendin 4, developed in the consortium for GLP-1 receptor imaging. (2) Devise novel imaging strategies by generating labelled “design” molecules/peptides/nanobody molecules targeting newly identified beta-cell surface proteins. These targets will be identified using a Systems Biology approach. For high-throughput tracer development, a stream-lined methodology will be established based on in vitro model systems and micro-/macroscopic in vivo real time dynamic imaging of tracer distribution by optical coherence tomography and complementary small animal PET and MRI. (3) Build on European excellence in tracer development using peptides, peptide-like and organic molecules for different imaging modalities. To achieve these ambitious goals, we have established a highly interdisciplinary and interactive project combining leading European research groups. In this way, a unique expertise is achieved regarding tracer development and imaging, beta-cells/diabetes and target definition.

Keywords: beta cell,pancreas,positron emission tomography,optical tomography,magnetic resonance imaging,tracer,diabetes,radiopeptides,affibody molecule,fluorescence,nanoparticles,specific targeting
Quality of maternal and prenatal care: bridging the know-do gap (QUALMAT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Germany,Belgium,Burkina Faso,Ghana,Sweden,Tanzania, United Republic of
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-05-01
End date: 2014-04-30
Duration (months): 60.0
Total project cost (EUR): 3736068.0
EU funding (EUR): 2915228.0
Participants: 6
Project status: CLOSED

Besides a dramatic lack of financial and human resources in developing countries, health care is additionally endangered by quality deficiencies caused by low staff motivation. This lack of motivation leads to an insufficient translation of knowledge into optimal utilization of resources. The “know-do” gap represents a challenge that must be addressed to strengthen health services performance towards achieving the Millennium Development Goals (MDGs). This is in particular true for some sensitive sectors like pre-natal and maternal health care. General objective of this research is to improve maternal health through better pre-natal and maternal care services offered by better motivated health workers. A computer-assisted clinical decision support system (CDSS) will be developed, implemented and tested aiming at (I) quality improvement of maternal and newborn care and (II) assessment of provider’s performance. Based on this tool a commonly agreed incentive scheme to increase motivation will be shaped and tested in three SSA - countries, namely Burkina, Ghana, and Tanzania. The incentive scheme might contain both non-monetary and monetary incentives and will be designed according to the human resource policy in the three countries. The planned approach is an implementation study with control arms containing one hospital and 6 first line health facilities in each of the study districts and an equal number of facilities in the control arm. A set of indicators for measurement of changes in quality of delivered services will be identified in order to follow up the sustainability and effectiveness of the strategies after their implementation. The study findings will allow understanding the important factors of staff motivation and facilitate adequate management for improvement of maternal and neonatal health care. “Knowing is not enough, we must apply; Wanting to do, is not enough, we must do it ” - J.W. v. Goethe

Keywords: prenatal and maternal health,newborn health,maternal and neonatal care quality of care,staff motivation,cdss,incentive schemes
NONHUMAN ADENOVIRUS VECTORS FOR GENE TRANSFER TO THE BRAIN (BRAINCAV)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: France,United Kingdom,Italy,Portugal,Spain,United Kingdom,Spain,Germany
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-10-01
End date: 2013-03-31
Duration (months): 54.0
Total project cost (EUR): 4325637.23
EU funding (EUR): 2984999.0
Participants: 11
Project status: CLOSED

Formidable challenges remain to prevent and treat successfully neurodegenerative diseases. Traditional pharmacological approaches, as well as those using stem cells, have made progress but their impact remain limited. As suggested by clinical results in Canavan and Parkinson’s disease, gene transfer offers substantial potential. However, this strategy of therapeutic intervention also brings unique obstacles - in particular the need to address feasibility, efficacy and safety. BrainCAV&amp;apos;s foundation is the potential of canine adenovirus type 2 (CAV-2) vectors, which preferentially transduce neurons and undergo a very efficient long-distance targeting via axonal transport. Moreover, the episomal long-term expression leads to safe, efficient neuron-specific gene delivery. We proposed a structured translational approach that spans basic research through pre-clinical model feasibility, efficacy and safety. To provide a proof-of-principle of the effectiveness of CAV-2, we tackle mucopolysaccharidosis type VII, a global, orphan disease commonly affecting children, and Parkinson&amp;apos;s disease, a focal degeneration of dopaminergic neurones commonly affecting aged population. To develop and execute this project, BrainCAV brings together an interdisciplinary combination of partners with unique expertise that will take CAV-2 vectors to the doorstep of clinical trials.

Keywords: brain,adenovirus,helper--dependent,neurons
A PHArmacogenomic study of Statins in the Elderly at risk for cardiovascular disease (PHASE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,United Kingdom,Ireland
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2012-06-30
Duration (months): 42.0
Total project cost (EUR): 3766919.2
EU funding (EUR): 2858188.0
Participants: 3
Project status: CLOSED

Cardiovascular disease is the leading cause of death in industrialized countries. The prevention of cardiovascular disease is critically dependent on lipid lowering therapy, which includes the 3-hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). Although statins are the most prescribed class of drugs worldwide, and therapy is generally associated with a reduction in risk for cardiovascular events by 20-30%, clinical response can be highly variable and adverse effects occur in a minority of patients. Recent research has provided evidence that in many cases, genetic variation contributes to this variable drug response. Research efforts should be made in analyzing the differences in genetic background to identify which genetic variation accounts for the variability in clinical response. Here we present a study that will establish in a large prospective randomized clinical trial with statin allocation which genetic variation is responsible for the variation in drug response. In 5804 participants of the PROspective Study of Pravastatin in the Elderly at risk (PROSPER) we will perform a genome-wide scan to assess the genetic variation responsible for variation in lowering low-density lipoprotein levels, in clinical outcome and for the occurrence of adverse effects. The unique character of the PROSPER study is that the study is randomized in three European countries, therefore all associations can be replicated in these countries. Positive associations will be confirmed in two comparable large clinical trials, the WOSCOPS and the CARE study. Cardiovascular pharmacogenomics will lead to improvements in the use of personalized therapy based on an individual’s genetic make-up. Non-responders or subjects who experience adverse effects will not be indicated for statin treatment when they are identified. This will increase the quality of life for many elderly people with polypharmacy and comorbidity and reduce costs for healthcare organizations.

Keywords: pharmacogenomics cardiovascular disease statins elderly
Comparative epidemiology of genetic lineages of Trypanosoma cruzi (CHAGASEPINET)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Belgium,Belgium,France,Sweden,Spain,Bolivia, Plurinational State of,Venezuela, Bolivarian Republic of,Argentina,Brazil,Colombia,Chile,Ecuador
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2012-12-31
Duration (months): 48.0
Total project cost (EUR): 3754260.0
EU funding (EUR): 2876507.0
Participants: 15
Project status: CLOSED

The focus of this multidisciplinary proposal is to elucidate the epidemiology of the genetic lineages of T. cruzi, for improved understanding and prevention of Chagas disease. The project will unite skills in genotyping, genomics, genetics and pathogenesis in Europe with considerable compatible skills in South America, and with key research in endemic areas that have distinct characteristics. The proposal is intended to be high impact in terms of both research progress and fostering of collaborative networks. Aim: Elucidate the epidemiology of the genetic lineages of T. cruzi, for improved understanding and prevention of Chagas disease. Technology development: 1. Develop further and apply MLST; PCR-RFLP and MLMT to the analysis of genetic populations of T. cruzi, 2. Sequence the unresolved genome of T. cruzi I, 3. Develop lineage specific diagnosis, 4. Develop an oligochromatography PCR-dipstick procedure for detection of T. cruzi. Molecular epidemiology: 5. Pilot studies of association between genetic lineage, clinical outcome, and prevalence of congenital infection, 6. Map the silvatic vector, silvatic mammal, human and ecological associations of the T. cruzi genotypes IId,e,b,a. 7. Compare lineage specific pathogenesis and transmissibility of congenital infection in a mouse model, and compare lineage susceptibility to drugs in vitro. Population genetics and phylogenetics: 8. Re-evaluate the population genetics and evolution of T. cruzi lineages. International cryobank and database: 9. Establish in South America an accessible, expanded, international cryobank for T. cruzi, 10. Establish a website and database for outputs of the project. The project encompasses the desirable characteristics prescribed by the call, in that they include: genomics/proteomics; effective, innovative relevance to disease, pathogenesis, drugs, interventions; an integrated multidisciplinarity, and capacity building, networking and training in endemic regions.

Keywords: trypanosomatidae trypanosoma cruzi chagas disease molecular epidemiology diagnosis pathogenesis disease control genomics population genetics phylogenetics
Exploiting Nanobodies in development of new diagnostic tools and treatment methods for Trypanosomiasis. (NANOTRYP)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Belgium,Mozambique,Switzerland,Belgium,Kenya,Spain
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2013-06-30
Duration (months): 54.0
Total project cost (EUR): 3407256.0
EU funding (EUR): 2714608.0
Participants: 6
Project status: CLOSED

African trypanosomiasis is in need of new diagnostic detection tools and new treatment methods. To date the widely used card agglutination test for trypanosomiasis is not very specific as the test is based on the screening for cross-reactive host antibodies. The availability of treatment for Trypanosmiasis on the other hand is limited due to the fact that only very few drugs are registered for use, and all can cause serious side effects in treated patients or animals. Hence, this project will focus on the development of new and innovative diagnosis and treatment tools, using the nanobody technology that has been developed by the coordinating partner of this network. Nanobodies are small single domain antibody fragments that have unique properties that include their capacity to recognize particular epitopes (not recognized by conventional antibodies) and their improved stability. In addition, they can be used as molecular target- or transport devices of other biological active components. As such they are excellent tools to support this project. Despite the fact that the coordinating laboratory has been a pioneer in differential molecular characterization of African trypanosomes and were involved in the initial release of diagnostic PCR methods that have now been adopted by many other research groups, this project will deliberately adopt a different approach. Indeed, in comparison to nanobody technology, PCR based diagnostics are much more costly and require an infrastructure that is hard to sustain over prolonged periods of time in African ‘field situations’. The simplicity of the nanobody technology on the other hand makes it an excellent topic for knowledge transfer. Despite it’s high-technology approach, the technique it will be relatively easy to be adopted by laboratories of participating African partner groups.

Keywords: nanobody,african trypanosomiasis
Establishment, Strategy and Initial activities of the TuBerculosis Vaccine Initiative : Coordination of European efforts with global research initiatives. (ESI-TBVI)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Coordination and support actions
Countries involved: Denmark,Germany,United Kingdom,Netherlands
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-05-01
End date: 2010-04-30
Duration (months): 24.0
Total project cost (EUR): 520146.22
EU funding (EUR): 429601.0
Participants: 5
Project status: CLOSED

The goal is to establish a TB Vaccine Initiative (TBVI) as a private public partnership. It will ensure an appropriate linkage between EC supported projects and global initiatives aiming at the development of new TB vaccines. TBVI will be established as a legal entity stemming from TBVAC, the FP6 EC supported project on TB vaccines, that has proven remarkably successful. TBVI will aim to facilitate the completion of vaccine development by their respective developers, and will not claim the ownership of any new products nor IP rights. Specific objectives of TBVI will be: a-To establish a working group to ensure coordination of activities related to TB vaccine development. It will comprise leaders of AERAS, BMGF, Stop TB (vaccines), TBVI and related EC projects. Regular meetings will be organized to define approaches regarding pre-clinical and clinical development. b- To advocate efforts towards the completion of TB vaccine development, including the mobilization of additional resources. c- To sustain and expand project management activities in the area of TB vaccine development . This will include advisory activities conducted through vaccine-specific product development teams (PDT) and management of specific European projects. The executive operational office will be based in ID-Lelystad (NL). A steering board comprising European scientists, with expertise in vaccine development, will meet on a monthly basis to decide on proposed and ongoing activities, development strategies and selection of new projects. A board of stakeholders/interested parties will review the overall activities and budget, and facilitate the mobilization of resources for TB vaccine development.

Keywords: coordination,advocacy,tb vaccine development,project management
OLIGOPEPTIDASE INHIBITORS IN BRAIN FUNCTION AND DYSFUNCTION: TOWARDS NEW THERAPEUTIC STRATEGIES FOR NEUROPROTECTION (NEUROPRO)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Belgium,Finland,Germany,Hungary,United Kingdom,Estonia,Belgium,Germany,Netherlands
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-10-01
End date: 2012-09-30
Duration (months): 48.0
Total project cost (EUR): 6290178.4
EU funding (EUR): 4788220.0
Participants: 12
Project status: CLOSED

At present more than 5 million people in the EU suffer from dementia and other neurodegenerative diseases and that number will grow as the average age of the population continues to increase. The efficacy of current medicines is limited and new therapeutic targets are sorely needed. Several independent lines of evidence have established an important role of prolyl oligopeptidase (PREP) in brain function and dysfunction. Aberrant PREP activity is involved in the progression of neurodegenerative disorders and PREP inhibitors are being developed for the treatment of memory and cognition deficits. Now a consortium of expert scientists from 8 academic institutes and 3 SME&apos;s come together for 4 years in this NEUROPRO project to boost European research aimed at 1) unravelling the biological role of PREP and PREP-like proteins in neuropathology, 2) determining the mode of action of PREP inhibitors and 3) firmly establishing their therapeutic potential. Specialists from different disciplines – cell and molecular biology, enzymology, chemistry, crystallography, biology and pharmacology – will work in a concerted and focussed way to achieve the goals using 6 work packages concentrating on PREP-regulated pathways in health and disease, PREP substrates, inhibitor target identification, drug development and validation, and generation of specific cell lines and animal models of neurodegenerative diseases. The SME’s involved are leaders in PREP inhibitor development and peptide analysis, and have in the past already brought novel therapeutics on the market. By the end of the project we expect to have proof of concept that PREP inhibition is a valid therapeutic target which will ultimately lead to new methods for the early detection, prevention or restoration of PREP-related neurodegeneration. The project also comprises instruments to translate basic research into clinical applications and will thus broaden the scope of treatments available to Europe&apos;s ageing population.

Keywords: prep prolyl-oligopeptidase neuropeptides inhibitor memory cognition neuroprotection